Acichek contains Omeprazole that is used for the treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.
Parietal (Stomach) cells secrete gastric acid through proton pumps. Proton pump is the final pathway for acid secretion in stomach cells, and inhibition of the pump leads to blocking of acid secretion. Omeprazole inhibits these proton pumps thereby reducing the secretion of acid in the stomach.
Omeprazole is prescribed in following conditions:
Gastro-oesophageal reflux disease
Prophylaxis of acid aspiration during general anaesthesia
Acichek is brand from Sanofi, a global healthcare leader with presence in more than 170 countries globally and nearly 79 manufacturing sites in 36 countries. Sanofi has created one of the first insulin formulations. As a health journey partner, Sanofi focuses on improving quality of life of patients. In 2016, Sanofi partnered with Verily to found Onduo, a joint-venture focusing on holistic solutions to improve diabetes management.
Your may have been prescribed Acichek because you could be suffering from Stomach Ulcers, Oesophageal Problems and other acidity related disorders.
Acichek is an orally available medication that contains the active substance Omeprazole. It works by reducing the amount of acid the stomach produces which helps heal any acid damage to the stomach and oesophagus.
Stomach ulcers are sores on the lining of the stomach and small intestine. This occurs when the protective mucus lining of the stomach becomes ineffective. If the mucus layer is worn away and stops functioning efficiently, the acid can damage the stomach tissue, causing an ulcer. Likewise, whenever the sphincter muscle at the lower end of the oesophagus relaxes at irregular time, allowing stomach acid to rush into the oesophagus which can cause heartburn and other signs.
Patients suffering from acidity related disorders like GERDs and stomach ulcers need to reduce the acid production in order to curb the damage to the stomach and oesophagus. Pantoprazole can be used to treat acidity-related disorders and symptoms that may include:
Gastroesophageal Reflux disease
Helicobacter pylori infection
Difficulty in swallowing
As directed by your Physician
As directed by your Physician
Adverse Reactions/ Side Effects
Significant: Hypomagnasaemia, cutaneous lupus erythematosus, SLE, osteoporosis-related fractures, fundic gland polyp, carcinoma, Clostridium) difficile-associated diarrhoea, interstitial nephritis, Vitamin B12 deficiency (long-term therapy), gastrointestinal infection (e.g. salmonella, Campylobacter). Gastrointestinal disorders: Nausea, vomiting, diarrhoea, constipation, flatulence, abdominal pain. General disorders and administration site conditions: Weakness, malaise. Hepatobiliary disorders: Increased liver enzymes. Immune system disorders: Urticaria. Metabolism and nutrition disorders: Peripheral oedema. Musculoskeletal and connective tissue disorders: Back pain. Nervous system disorders: Headache, dizziness, somnolence, paraesthesia, vertigo. Psychiatric disorders: Insomnia. Respiratory, thoracic and mediastinal disorders: Cough. Skin and subcutaneous tissue disorders: Rash, dermatitis, pruritus.
Warnings and Precautions
Patient with reduced body store or risk factors for reduced vitamin B12 absorption; risk of osteoporosis. Hepatic impairment. Children, elderly. Pregnancy and lactation. CYP2C19 ultrarapid metabolisers. Monitoring Parameters Rule out gastric malignancy prior to initiation of treatment. Monitor Mg concentrations prior to initiation and periodically thereafter.
Concomitant use with nelfinavir.
May decrease plasma concentrations of nelfinavir and atazanavir. Increased risk of hypomagnesaemia with diuretics. May increase plasma concentration of tacrolimus, methotrexate. May decreased absorption of itraconazole, ketoconazole, posaconazole, erlotinib. May decrease metabolism of diazepam, phenytoin, cilostazol. May reduce the antiplatelet activity of clopidogrel. May increase bioavailability of digoxin.
Symptoms: Nausea, vomiting, dizziness, abdominal pain, diarrhoea, headache apathy, depression and confusion. Management: Symptomatic and supportive treatment.
Intravenous: Store below 25°C. Protect from light and moisture. Oral: Store below 25°C. Protect from light and moisture.
Mechanism of Action
Omeprazole is a substituted benzimidazole gastric antisecretory agent and is also known as proton pump inhibitor (PPI). It blocks the final step in gastric acid secretion by specific inhibition of adenosine triphosphatase (ATPase) enzyme system present on the secretory surface of the gastric parietal cell. Both basal and stimulated acid are inhibited.